Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Why XOM is close to an ideal option trading candidate

XOM has a hugely active options series, trades in both monthly and weekly expiration series and has bid / ask spreads that are just a few pennies wide. One of the most interesting aspects of options is the myriad opportunities presented for high probability trades for thos...
J.W. Jones | February 6, 2013 |

Alpine Immune Shares Soar 160% on Global Option and License Agreement with AbbVie

Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101. Clinical-stage immunotherapy company Alpine Immune S...
Streetwise Reports | June 19, 2020 |

Why You May Want to Avoid Buying Options This Week

If you do not understand implied volatility and you are buying put or call options or some combination, you have been warned! The market continues to move very fast, has large swings, and one would think that makes it an excellent time to buy options for huge gains, r...
Chris Vermeulen | March 10, 2020 |

How to trade gold with ETFs and options

With few exceptions , most leading financial gurus agree that every portfolio should include some physical gold. But while the yellow metal itself is great as a long-term hedge against turmoil and inflation, it's a lousy trading vehicle. Here's why. For shorter-term t...
Larry D. Spears | October 28, 2012 |

A world energy crisis driving a renewed interest in uranium

Welcome to The Market Herald Canada’s Capital Compass. Many companies are considering a new path to clean energy in the fight against climate change. Our next company is publicly traded on the venture exchange and is utilizing uranium in this pursuit...
Brieanna McCutcheon | October 24, 2023 |

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise

Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity fin...
Streetwise Reports | January 6, 2020 |

Calculate the Trading Strategies' Profitability like a Pro

Investors venture into cryptocurrency trading to gain profits. They employ customized trading strategies, portfolio management strategies, and progressive investment decisions throughout their trade. Due to the progressive nature of trading, tracking one&CloseCurlyQuote...
Julia Beyers | September 5, 2019 |

Pampa Metals: Unveiling the Piuquenes Copper Gold Project

The following is a transcription of the above video, and The Market Herald Canada has edited it for clarity . Simply put Pampa Metals (CSE:PM) is a Vancouver‐based post-discovery copper porphyry exploration company listed on the Canadian Stock Exchange, Frank...
Brieanna McCutcheon | January 30, 2024 |

Immuno-Oncology Firm Expands Agreement with AbbVie

The revisions to the existing arrangement between the two U.S. firms are discussed in a ROTH Capital Partners report. In a Nov. 21 research note, ROTH Capital Partners analyst Zegbeh Jallah reported that Harpoon Therapeutics Inc. (HARP:NASDAQ) and AbbVie Inc. (ABBV...
Streetwise Reports | December 5, 2019 |

First Helium creates two premium helium projects in Alberta

The Alberta-focused, cash-flowing, multi-project helium developer First Helium stock (TSXV:HELI) is seeing a demand for its assets. The company has two premier helium projects in Alberta that are high-value, low risk to high-impact exploration opportunities. The company...
Brieanna McCutcheon | July 5, 2023 |
1 2 3 4 5 6 7 8 9 10 ...